A Review of the Association between Osteosarcoma Metastasis and Protein Translation

Journal of Comparative Pathology

Volumn 146, Issue 2-3, 2012, Pages 132-142

  Osborne, T S ^a   Khanna, C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dog; Metastasis; Osteosarcoma; Protein translation

Indexed keywords

ALPHA INTERFERON; CISPLATIN; CYCLIN D1; DOXORUBICIN; ELONGATION FACTOR; ETOPOSIDE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HEPARANASE; IFOSFAMIDE; INTERLEUKIN 8; MESSENGER RNA; METHOTREXATE; MYC PROTEIN; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSFER RNA; VASCULOTROPIN;

CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CAUSE OF DEATH; DISEASE ASSOCIATION; EVENT FREE SURVIVAL; GENE MUTATION; HUMAN; LONG TERM CARE; LUNG METASTASIS; MAINTENANCE THERAPY; MALIGNANT TRANSFORMATION; METASTASIS; MULTIMODALITY CANCER THERAPY; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RACE; RECURRENCE FREE SURVIVAL; REVIEW; SEX DIFFERENCE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; BONE NEOPLASMS; DOG DISEASES; DOGS; NEOPLASM METASTASIS; OSTEOSARCOMA; PROTEIN BIOSYNTHESIS;

CANIS FAMILIARIS;

EID: 84858623789     PISSN: 00219975     EISSN: 15323129     Source Type: Journal    
DOI: 10.1016/j.jcpa.2011.12.007     Document Type: Review

References (92)

1. Bacci G., Rocca M., Salone M., Balladelli A., Ferrari S., et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. Journal of Surgical Oncology 2008, 98:415-420.
2. Baserga R. The cell cycle: myths and realities. Cancer Research 1990, 50:6769-6771.
3. Beavon I.R. The E-cadherin-catenin complex in tumour metastasis: structure, function and regulation. European Journal of Cancer 2000, 36:1607-1620.
4. Berkel H., Turbat-Herrera E., Shi R., De Benedetti A. Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiology, Biomarkers and Prevalence 2001, 10:663-666.
5. Berman S.D., Calo E., Landman A.S., Danielian P.S., Miller E.S., et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proceedings of the National Academy of Sciences USA 2008, 105:11851-11856.
6. Bielack S.S., Kempf-Bielack B., Delling G., Exner G.U., Flege S., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of Clinical Oncology 2002, 20:776-790.
7. Bjornsti M.A., Houghton P.J. The TOR pathway: a target for cancer therapy. Nature Reviews Cancer 2004, 4:335-348.
8. Blouin S., Basle M.F., Chappard D. Rat models of bone metastases. Clinical and Experimental Metastasis 2005, 22:605-614.
9. Clemens M.J., Bommer U.A. Translational control: the cancer connection. International Journal of Biochemistry and Cell Biology 1999, 31:1-23.
10. Crew J., Fuggle S., Bicknell R., Cranston D., De Benedetti A., et al. Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression. British Journal of Cancer 2000, 82:161-166.
11. Dahlin D., Coventry M. Osteogenic osteosarcoma. A study of six hundred cases. Journal of Bone and Joint Surgery 1967, 49:101-110.
12. De Benedetti A., Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23:3189-3199.
13. De Benedetti A., Joshi B., Graff J., Zimmer S. CHO cells transformed by the translation factor eIF-4E display increased c-myc expression but require overexpression for Max tumorigenicity. Molecular and Cellular Differentiation 1994, 2:347-371.
14. De Benedetti A., Rhoads R.E. Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology. Proceedings of the National Academy of Sciences USA 1990, 87:8212-8216.
15. De Nigris F., Rossiello R., Schiano C., Arra C., Williams-Ignarro S., et al. Deletion of Yin Yang 1 protein in osteosarcoma cells on cell invasion and CXCR4/angiogenesisand metastasis. Cancer Research 2008, 68:1797-1808.
16. DeFatta R.J., Nathan C.O., De Benedetti A. Antisense RNA to eIF4E suppresses oncogenic properties of a head and neck squamous cell carcinoma cell line. Laryngoscope 2000, 110:928-933.
17. Douma S., Van Laar T., Zevenhoven J., Meuwissen R., Van Garderen E., et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004, 430:1034-1039.
18. Fan T.M. Animal models of osteosarcoma. Expert Reviews of Anticancer Therapy 2010, 10:1327-1338.
19. Fidler I.J., Naito S., Pathak S. Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice [corrected]. Cancer Metastasis Reviews 1990, 9:149-165.
20. Franklin S., Pho T., Abreo F., Nassar R., De Benedetti A., et al. Detection of the proto-oncogene eIF4E in larynx and hypopharynx cancers. Archives of Otolaryngology and Head and Neck Surgery 1999, 125:177-182.
21. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. Journal of Cell Biology 1994, 124:619-626.
22. Fu X.Y., Besterman J.M., Monosov A., Hoffman R.M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proceedings of the National Academy of Sciences USA 1991, 88:9345-9349.
23. Gingras A., Raught B., Sonenberg N. eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annual Reviews of Biochemistry 1999, 68:913-963.
24. Graff J.R., Boghaert E.R., De Benedetti A., Tudor D.L., Zimmer C.C., et al. Reduction of translation initiation factor 4E decreases the malignancy of ras-transformed cloned rat embryo fibroblasts. International Journal of Cancer 1995, 60:255-263.
25. Graff J.R., Konicek B.W., Lynch R.L., Dumstorf C.A., Dowless M.S., et al. eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. Cancer Research 2009, 69:3866-3873.
26. Graff J.R., Zimmer S.G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clinical and Experimental Metastasis 2003, 20:265-273.
27. Griffiths G., Grundl M., Leychenko A., Reiter S., Young-Robbins S., et al. Bit-1 mediates integrin-dependent cell survival through activation of the NFkappaB pathway. Journal of Biological Chemistry 2011, 286:14713-14723.
28. Grossmann J. Molecular mechanisms of 'detachment-induced apoptosis-Anoikis'. Apoptosis 2002, 7:247-260.
29. Guo Y., Rubin E., Xie J., Zi X., Hoang B. Dominant negative LRP5 decreases tumorigenicity and metastasis of osteosarcoma in an animal model. Clinical Orthopaedic Related Research 2008, 466:2039-2045.
30. Gurney J.G., Swensen A.R., Bulterys M. Malignant Bone Tumors 1999, NIH Publication Number 99-4649, Bethesda, pp. 99-110.
31. Hansen M.F. Molecular genetic considerations in osteosarcoma. Clinical Orthopaedic Related Research 1991, 270:237-246.
32. Hart I., Fiddler I. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Research 1980, 40:2281-2287.
33. Hattinger C., Pasello M., Ferrari S., Picci P., Serra M. Emerging drugs for high-grade osteosarcoma. Expert Opinion in Emerging Drugs 2010, 15:615-634.
34. Hayden J.B., Hoang B.H. Osteosarcoma: basic science and clinical implications. Orthopaedic Clinics of North America 2006, 37:1-7.
35. Hoffman R.M. Clinically accurate orthotopic mouse models of cancer. Methods in Molecular Medicine 2001, 58:251-275.
36. Hunter K.W. Ezrin, a key component in tumor metastasis. Trends in Molecular Medicine 2004, 10:201-204.
37. Hunter K.W., Crawford N.P., Alsarraj J. Mechanisms of metastasis. Breast Cancer Research 2008, 10(Suppl. 11):S12.
38. Huvos A.G., Rosen G., Marcove R.C. Primary osteogenic osteosarcoma: pathogenic aspects in 20 patients after treatment with chemotherapy, en bloc resection, and prosthetic bone replacement. Archives in Pathology and Laboratory Medicine 1977, 101:14-18.
39. Jiang Y., Muschel R.J. Regulation of matrix metalloproteinase-9 (MMP-9) by translational efficiency in murine prostate carcinoma cells. Cancer Research 2002, 62:1910-1914.
40. Kansara M., Thomas D.M. Molecular pathogenesis of osteosarcoma. DNA and Cell Biology 2007, 26:1-18.
41. Kerekatte V., Smiley K., Hu B., Smith A., Gelder F., et al. The proto-oncogene/translation factor eIF4E: a survey of its expression in breast carcinomas. International Journal of Cancer 1995, 64:27-31.
42. Khanna C. Novel targets with potential therapeutic applications in osteosarcoma. Current Oncology Reports 2008, 10:350-358.
43. Khanna C., Prehn J., Yeung C., Caylor J., Tsokos M., et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clinical and Experimental Metastasis 2000, 18:261-271.
44. Krishnan K., Bruce B., Hewitt S., Thomas D., Khanna C., et al. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clinical and Experimental Metastasis 2006, 23:227-236.
45. Krishnan K., Khanna C., Helman L.J. The biology of metastases in pediatric sarcomas. Cancer Journal 2005, 11:306-313.
46. Kumar V., Abbas A., Fausto N. Robbins' and Cotran's Pathologic Basis of Disease 2005, Elsevier Saunders, Philadelphia, pp. 309-313.
47. Lazaris-Karatzas A., Montine K.S., Sonenberg N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap. Nature 1990, 345:544-547.
48. Lehninger A., Nelson D., Cox M. Principles of Biochemistry 1993, Worth Publishers, New York, pp. 905-923.
49. Li Y., DeFatta R., Anthony C., Sunavala G., De Benedetti A. A translationally regulated tousled kinase phosphorylates histone H3 and confers radioresistance when overexpressed. Oncogene 2001, 20:726-738.
50. Luzzi K.J., MacDonald I.C., Schmidt E.E., Kerkvliet N., Morris V.L., et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. American Journal of Pathology 1998, 153:865-873.
51. Malawar M., Helman L., O'Sullivan B. Cancer Principles and Practice of Oncology 2005, 1638-1686. Lippincott Williams & Wilkins, Philadelphia. V. De Vita, S. Hellman, S.A. Rosenburg (Eds.).
52. Mamane Y., Petroulakis E., Rong L., Yoshida K., Ler L.W., et al. eIF4E - from translation to transformation. Oncogene 2004, 23:3172-3179.
53. Matthews-Greer J., Caldito G., De Benedetti A., Herrera G., Dominguez-Malagon H., et al. eIF4E as a marker for cervical neoplasia. Applied Immunohistochemistry and Molecular Morphology 2005, 13:367-370.
54. Mendoza M., Khanna C. Revisiting the seed and soil in cancer metastasis. International Journal of Biochemistry and Cell Biology 2009, 41:1452-1462.
55. Meyers P.A. Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma. Expert Reviews of Anticancer Therapy 2009, 9:1035-1049.
56. Nathan C.A., Carter P., Liu L., Li B.D., Abreo F., et al. Elevated expression of eIF4E and FGF-2 isoforms during vascularization of breast carcinomas. Oncogene 1997, 15:1087-1094.
57. Nathan C.A., Liu L., Li B.D., Abreo F.W., Nandy I., et al. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer. Oncogene 1997, 15:579-584.
58. Osborne T., Ren L., Healey J.H., Shapiro L.Q., Chou A.J., et al. Evaluation of eIF4E expression in an osteosarcoma-specific tissue microarray. Journal of Pediatric Hematology and Oncology 2011, 33:524-528.
59. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 1:571-573.
60. Pain V.M. Initiation of protein synthesis in eukaryotic cells. European Journal of Biochemistry 1996, 236:747-771.
61. Paoloni M., Davis S., Lana S., Withrow S., Sangiorgi L., et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics 2009, 10:625.
62. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature Reviews Cancer 2008, 8:147-156.
63. Paoloni M.C., Mazcko C., Fox E., Fan T., Lana S., et al. Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One 2010, 5:e11013.
64. Posthuma-DeBoer J., Witlox M., Kaspers G., van Royen B. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clinical and Experimental Metastasis 2011, 28:493-503.
65. Rhoads R.E., Joshi-Barve S., Rinker-Schaeffer C. Mechanism of action and regulation of protein synthesis initiation factor 4E: effects on mRNA discrimination, cellular growth rate, and oncogenesis. Progress in Nucleic Acid Research and Molecular Biology 1993, 46:183-219.
66. Richter J.D., Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005, 433:477-480.
67. Rinker-Schaeffer C.W., Graff J.R., De Benedetti A., Zimmer S.G., Rhoads R.E. Decreasing the level of translation initiation factor 4E with antisense RNA causes reversal of ras-mediated transformation and tumorigenesis of cloned rat embryo fibroblasts. International Journal of Cancer 1993, 55:841-847.
68. Rosenwald I., Chen J., Wang S., Savas L., London I., et al. Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis. Oncogene 1999, 18:2507-2517.
69. Rosenwald I., Hutzler M., Wang S., Savas L., Fraire A. Expression of eukaryotic translation initiation factors 4E and 2alpha is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung. Cancer 2001, 92:2164-2171.
70. Rousseau D., Kaspar R., Rosenwald I., Gehrke L., Sonenberg N. Translation initiation of ornithine decarboxylase and nucleocytoplasmic transport of cyclin D1 mRNA are increased in cells overexpressing eukaryotic initiation factor 4E. Proceedings of the National Academy of Sciences USA 1996, 93:1065-1070.
71. Ruoslahti E., Reed J.C. Anchorage dependence, integrins, and apoptosis. Cell 1994, 77:477-478.
72. Saito H., Hayday A.C., Wiman K., Hayward W.S., Tonegawa S. Activation of the c-myc gene by translocation: a model for translational control. Proceedings of the National Academy of Sciences USA 1983, 80:7476-7480.
73. Sauer B., Henderson N. The cyclization of linear DNA in Escherichia coli by site-specific recombination. Gene 1988, 70:331-341.
74. Scott P., Smith K., Poulsom R., De Benedetti A., Bicknell R., et al. Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. British Journal of Cancer 1998, 77:2120-2128.
75. Seki N., Takasu T., Mandai K., Nakata M., Saeki H., et al. Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clinical Cancer Research 2002, 8:3046-3053.
76. Slauson D., Cooper B. Mechanisms of Disease: a Textbook of Comparative General Pathology 2002, Mosby, St Louis, pp. 341-353.
77. Sonenberg N., Dever T. Eukaryotic translation initiation factors and regulators. Current Opinions in Structural Biology 2003, 13:56-63.
78. Sonenburg N., Gingras A. The mRNA 5' cap-binding protein eIF4E and control of cell growth. Current Opinions in Cell Biology 1998, 10:268-275.
79. Stacey D. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Current Opinions in Cell Biology 2003, 15:158-163.
80. Vail D.M., MacEwen E.G. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigations 2000, 18:781-792.
81. Walkley C.R., Qudsi R., Sankaran V.G., Perry J.A., Gostissa M., et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes and Development 2008, 22:1662-1676.
82. Wan X., Mendoza A., Khanna C., Helman L.J. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Research 2005, 65:2406-2411.
83. Wang L.L. Biology of osteogenic sarcoma. Cancer Journal 2005, 11:294-305.
84. Wang S., Rosenwald I., Hutzler M., Pihan G., Savas L., et al. Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. American Journal of Pathology 1999, 155:247-255.
85. Weiss L., Nannmark U., Johansson B.R., Bagge U. Lethal deformation of cancer cells in the microcirculation: a potential rate regulator of hematogenous metastasis. International Journal of Cancer 1992, 50:103-107.
86. Weiss L., Orr F., Honn K. Interactions of cancer cells with the microvasculature during metastasis. FASEB Journal 1988, 2:12-21.
87. Whelan J., Weeden S., Uscinska B., McTiernan A. Localized extremity osteosarcoma: mature survival data from two European osteosarcoma intergroup randomised clinical trials. Proceedings of the American Society of Clinical Oncology 2000, 19:1281a.
88. Withrow S.J., Khanna C. Bridging the gap between experimental animals and humans in osteosarcoma. Cancer Treatment and Research 2009, 152:439-446.
89. Withrow S.J., Wilkins R.M. Cross talk from pets to people: translational osteosarcoma treatments. ILAR Journal 2010, 51:208-213.
90. Witz I.P., Levy-Nissenbaum O. The tumor microenvironment in the post-PAGET era. Cancer Letters 2006, 242:1-10.
91. Yang L., Kuang L.G., Zheng H.C., Li J.Y., Wu D.Y., et al. PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma. World Journal of Gastroenterology 2003, 9:35-39.
92. Zimmer S.G., DeBenedetti A., Graff J.R. Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Research 2000, 20:1343-1351.